Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer and other severe diseases. The company has pioneered a new category of ultra-tunable peptide therapeutics called Helicons, which combine the strengths of small molecules and monoclonal antibodies to achieve outcomes previously considered impossible. Parabilis's custom-built research engine is designed to tackle previously undruggable biology targets, and the company has demonstrated clinical proof-of-concept for its approach. Headquartered in Cambridge, Massachusetts, Parabilis raised $305M in early 2026 to advance its pipeline of Helicon-based cancer therapies.